

MINUTES OF DRUG AND THERAPEUTICS COMMITTEE

Date of Meeting : 13-03-2025
Time : 3:00 PM
Venue : Forensic Demonstration Hall
Chairman : Dr. Rajesh Anto, Medical Superintendent
Vice Chairman : Fr. Jaison Mundanmani CMI, Joint Director
Secretary : Dr. Lejo Jacob A

PROCEDURE & DECISIONS:

The meeting started with a silent prayer. Dr. Laween welcomed all the DTC members to the gathering. Dr. Filmie, Clinical Pharmacist presented the previous meeting minutes, Agenda and new formulary drugs. Pharmacovigilance report and a short session on TDM was presented by Dr. Prathibha, Department of Pharmacology. The meeting winds up with thanks giving by Fr. Deljo Puthoor CMI.


The following points were discussed in the meeting.

AGENDA


1. New formulary drugs
2. Hospital formulary 2025 updation
3. LASA drug list 2025 updation
4. Drug recall forms
5. Pharmacovigilance Report
6. Therapeutic drug monitoring
7. Awareness session on Prescription writing

Previous Meeting Points:

Sl. No.	Points discussed	Suggested action	Responsible Dept./Person	Due date
1.	Welcomed all Committee Members	Committee wholeheartedly welcomed all the members who were present at the 26th DTC meeting.	DTC	NA
2.	New Formulary Drugs	15 new drugs were discussed and added to the hospital formulary after the approval of the DTC committee. Newer Antibiotics - Cefepime/Enmetazobactam and Tedizolid were discussed in detail by Dr. Tabitha regarding their coverage, indications, doses and prize.	Dr. Irin	NA




3.	NCC-MERP Classified Error	Out of 510 cases audited, the errors were categorized as per NCC- MERP Tool based on their severity. It includes 224 category A errors, 44 category B errors and 8 category C errors.	Clinical pharmacy dept.	Ongoing
4.	High Risk Medication Audit	620 high risk medications were audited. No dose was found for 3 drugs, no route for 3 drugs, no frequency for 9 drugs, no prescribers name for 90 cases and no prescribers sign for 132 drugs.	Clinical pharmacy dept.	Ongoing
5.	VTE Audit	<p>As per the last DTC meeting recommendation, a retrospective and prospective data collection was done to find the VTE incidence at our hospital.</p> <p>Retrospective data for 18 months was collected from the MRD for VTE/DVT/PE coded files. The total no. of VTE patients for the specified period was 62 patients.</p> <p>Prospective data for 1 month was done by clinical pharmacy dept. and 14 VTE patients were recorded. The incidence percentage for the month was 0.36%.</p> <p>The VTE diagnosis not being included in the diagnosis of some discharge summaries, use of terms other than VTE/DVT/PE, and cases not being coded are the few reasons for the disparity in the two data, which were also mentioned.</p> <p>Dr.Rajesh Anto discussed the importance of VTE risk assessment, VTE prophylaxis and the need for implementing a protocol at our hospital was highlighted. The same has to be discussed in the next doctors meeting.</p>	Clinical pharmacy dept. & Dr. Rajesh Anto, Dr. Joe	Ongoing
6.	ADR Report	<p>Total number of ADRs reported from September to November 2024 was 200. Out of which 52 cases were spontaneous and 148 cases were active reported cases.</p> <p>ADR reports were classified as Month wise, drug wise and department wise ADR reports. The need for more spontaneous reporting of ADR was emphasized.</p> <p>Drug safety alerts issued by the Indian pharmacopoeia commission on Tetracycline, Amphotericin B and Carbimazole were discussed.</p>	Dr. Prathibha V K	Ongoing




7.	Quality Report on Drug related errors	iApps through Event reported errors on administration, documentation, intending and policy violation were discussed along with its root cause analysis and CAPA. It includes 12 administration errors, 8 documentation errors and 1 dispensing error.	Mrs. Susmi	Ongoing
----	--	---	------------	---------

Present Discussion Points

Sl. No.	Points discussed	Suggested action	Responsible Dept./Person	Due date
1.	Welcomed all Committee Members	Committee wholeheartedly welcomed all the members who were present at the 27th DTC meeting.	DTC	NA
2.	New Formulary Drugs	8 new drugs were discussed and added to the hospital formulary after the approval of the DTC committee.	DTC	NA
3.	Hospital formulary & LASA drug list 2025 updation	The updated versions of Hospital formulary 2025 and LASA drug list 2025 was approved by the DTC committee and to be updated in Oneamala.	Clinical pharmacy	Done
4.	Drug recall forms	Defective product complaint form and Product recall form was reviewed by the DTC committee. The forms were approved after a few changes by the committee and implemented.	Pharmacy	Done
5.	Pharmacovigilance Report	Total number of ADRs reported from December 2024 to February 2025 was 97. The highest no. of ADRs were reported from the department of general medicine, followed by emergency medicine and pulmonology. A brief discussion on a case of patient death after administration of inj. Cefoperazone/sulbactam was held. Drug safety alerts from the PvPI on amphotericin, carbimazole and beta blockers were discussed and asked to report such ADR if	Dr. Prathibha	Ongoing




		observed to the Pharmacovigilance department.		
6.	Therapeutic drug monitoring	Discussion was carried out on Therapeutic Drug Monitoring system- machines used, technologies involved, feasibility and cost. The list of drugs which can be analyzed by the auto analyzer now available in the biochemistry was displayed. Also displayed the list of drug kits available for auto analyzer by thermofisher. The drug kits available, expiry of these kits and no.of samples which can be analyzed were also discussed. Cyclosporine, posaconazole, carmazepine phenytoin, etc were a few suggested drugs. Requested all departments to provide an individual list of possible TDM measuring drugs.	Dr. Prathibha	
7.	Awareness session on Prescription writing	A brief session on minimum requirements of a prescription – both IP & OP prescriptions and the importance of compliance in kardex filling was emphasized. Formulary compliance, drug reconciliation for all IP patients, generic names of drugs, capital letters for all drugs, right dose, route, frequency and duration significance was high lightened. Suggestion was put forth on adding Prescribed time and Registration number to the kardex.	Dr. Laween Quality control dept.	To be considered in the next kardex revision



Dr. Lejo Jacob A
 Secretary


Dr. Rajesh Anto
 Chairman





Dr. BETSY THOMAS
 MD, FRCOG, DNB, MICOG
 PRINCIPAL
 AMALA INSTITUTE OF MEDICAL SCIENCES
 AMALA NAGAR, THRISSUR-680 555





Drug and Therapeutic Committee



Betsy
Dr. BETSY THOMAS
 MD, FRCOG, DNB, MICOG
 PRINCIPAL

AMALA INSTITUTE OF MEDICAL SCIENCES
 AMALA NAGAR, THRISSUR-680 555

Amala Institute of Medical Sciences (An Undertaking of Amala Cancer Hospital Society)
 Affiliated to Kerala University of Health Sciences Accredited by KUHS with QAS A+ Grade &
 NABH & NABL Accredited & ISO 9001:2015 Certified, Amala Nagar P.O, Thrissur, Kerala.
 Ph: +91 487 2304000, 2304070 | Fax: +91 487 2307969 | urooncology@amalaims.org
 www.amalaims.org | Follow us on

